DFINE, Inc., the developer of minimally invasive radiofrequency (RF)
targeted therapies for the treatment of vertebral pathologies, today
announced an upcoming poster presentation at the World
Congress of Interventional Oncology (WCIO), June 14-18 in Chicago.
The poster, "Radiofrequency Ablation and Vertebral Augmentation of Bone
Metastasis of the Spine: Early Experience of a Novel Minimally-Invasive
Technology," will be presented on Thursday, June 14 at 9:30-10:30 a.m.
and 3:45-5:00 p.m. and on Saturday, June 16 at 4:00-5:00 p.m. The poster
covers the initial pre-clinical and clinical use of the STAR™
Tumor Ablation System using targeted radiofrequency ablation (t-RFA)
for the treatment of metastatic vertebral body tumors.
"Our goal is to work closely with the interventional and oncology
professional communities to obtain clinical evidence and continually
advance our knowledge of the role of t-RFA with the STAR System in the
palliative treatment of patients with painful vertebral body
metastasis," said Kevin Mosher, Chief Executive Officer of DFINE. "Early
results have been encouraging, and we are pleased to share this data
with the Interventional Oncology Community at WCIO."
DFINE recently completed the initial phase of its U.S. commercial
release of the STAR System. More than 50 patients have been treated at
26 centers across the country since the initial product rollout in March
Unlike other currently available ablation devices designed for soft
tissue, the STAR System was developed specifically for bone and the
unique anatomy of the spine. The benefits of the system include: